https://scholars.lib.ntu.edu.tw/handle/123456789/469821
標題: | The best usage of aspirin in primary prevention - Indication, dosage and ethnic issues | 作者: | Lin C.-S. Sheu W.H.-H. Chern C.-M. CHAU-CHUNG WU Ho L.-T. Hsu C.Y. Hsu T.-L. Lo Y.-K. MING-FONG CHEN |
關鍵字: | Aspirin; Diabetes; Dosage; Metabolic syndrome; Primary prevention; Stroke | 公開日期: | 2007 | 卷: | 18 | 期: | 1 | 起(迄)頁: | 1-10 | 來源出版物: | Journal of Internal Medicine of Taiwan | 摘要: | Aspirin is a well-known drug applied in clinical therapy. However, results of aspirin researches and clinical trials are different from traditional therapeutical guidelines. Some new conclusions emerged. Aspirin takes in a prevention role in some diseases, such as cardiovascular (CV) events, diabetes, and metabolic syndrome. However, how to apply aspirin in primary prevention still needs more discussion. In this article, we discuss the effect of aspirin in the field of cardiology, stroke, diabetes and pharmacology. We also discuss the dosage and appropriate usage of aspirin in Taiwan's population. The content of this article included the view points of the benefit of aspirin in the prevention of CV events from cardiologist's, diabetologist's and neurologist's view. We also discuss the starring role of aspirin from pharmacological issues or clinical reality? The conclusions are that enteric-coated aspirin has good gastrointestinal tolerability than common caplets; Anti-platelet therapies such as long-term use of low dose aspirin (75-150 mg/day) can significantly reduce cardiovascular events; Aspirin can reduce the risk of first stroke in women and myocardial infarction in man; It also can reduce the risk of cardiovascular events in diabetes. Besides, American Heart Association and American Diabetes Association recommend that aspirin can be used as primary and secondary prevention in high risk population of cardiovascular disease. The individual management is recommended when people who have high risk of CV events and use aspirin in primary or secondary prevention. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-33947631360&partnerID=40&md5=123b7f31b814fa685b230b65f1de371f https://scholars.lib.ntu.edu.tw/handle/123456789/469821 |
ISSN: | 1016-7390 | SDG/關鍵字: | acetylsalicylic acid; antithrombocytic agent; clopidogrel; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; naproxen; placebo; rofecoxib; article; cardiovascular disease; cerebrovascular accident; clinical trial; diabetes mellitus; drug dosage form comparison; drug formulation; drug indication; drug tolerance; drug use; ethnic difference; heart infarction; high risk population; human; low drug dose; medical practice; medical research; medical society; metabolic syndrome X; primary prevention; risk reduction; Taiwan |
顯示於: | 醫學教育暨生醫倫理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。